Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

imatinib mesylate

Trial Locations (29)

112

Novartis Investigative Site, Taipei

1006

Novartis Investigative Site, Tunis

2193

Novartis Investigative Site, Parktown

10002

Novartis Investigative Site, Taipei

10330

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

11211

Novartis Investigative Site, Riyadh

33305

Novartis Investigative Site, Lin-Ko

40705

Novartis Investigative Site, Taichung

83301

Novartis Investigative Site, Niaosong Township

90110

Novartis Investigative Site, Songkhla

110044

Novartis Investigative Site, New Delhi

198255

Novartis Investigative Site, Saint Petersburg

305035

Novartis Investigative Site, Kursk

380009

Novartis Investigative Site, Ahmedabad

400016

Novartis Investigative Site, Mumbai

420029

Novartis Investigative Site, Kazan'

620036

Novartis Investigative Site, Yekaterinburg

644013

Novartis Investigative Site, Omsk

664035

Novartis Investigative Site, Irkutsk

016000

Novartis Investigative Site, Algiers

Unknown

Novartis Investigative Site, Al Mansurah

Novartis Investigative Site, Cairo

Novartis Investigative Site, Amman

Novartis Investigative Site, Tainan City

411 001

Novartis Investigative Site, Pune

1107 2020

Novartis Investigative Site, Beirut

06100

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY